By simultaneously targeting two opioid receptor subtypes, researchers from Wake Forest School of Medicine and Astraea Therapeutics Inc. have developed a compound that, in nonhuman primates, was an effective analgesic that not only lacked the rewarding effects of currently used opioid analgesic, but blocked those effects, making it a potential treatment for both pain and opioid addiction.